1. Scrip
  2. >>R&D
  3. >>Clinical Trials

DalCor Keeps Faith In CETP Biomarker, Despite No Dice For Merck's REVEAL Genetic Analysis

 
• By Emily Hayes

Hopes for a precision approach for the vast cardiovascular disease population live on – past failed studies of HDL-raising drugs and lack of evidence for genetic typing in Merck's latest analysis of anacetrapib in REVEAL.

Cholesteryl ester transfer protein (3d structure) with a potential use in atherosclerosis therapy. It facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. - Illustration
Three-dimensional illustration of cholesteryl ester transfer protein (CETP), which facilitates the transport of cholesteryl esters and triglycerides between lipoproteins.

DalCor Pharmaceuticals says it's still confident about its dal-GenE outcomes study of genetically selected patients treated with the cholesterol-modulating CETP inhibitor dalcetrapib, but the odds on its big gamble are arguably worsening after a new analysis of Merck & Co. Inc.'s REVEAL outcomes study of anacetrapib did not support the hypothesis.

A retrospective analysis of data from Merck's massive REVEAL outcomes study of its CETP inhibitor anacetrapib, presented at the American...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 
• By Anju Ghangurde

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

Four Chinese Firms Snag Global First-In-Class Approvals In China

 
• By Dexter Jie Yan

Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.

More from R&D

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.

Lupin’s Cimzia Biosimilar Candidate Reflects Strategy To Separate Wheat From Chaff

 
• By Vibha Ravi

Lupin's choice of a Cimzia biosimilar candidate and partnering with Zentiva reflect a strategy to sort the wheat from the chaff. Of 118 biologics to lose patent protection between 2025 and 2034 as per IQVIA, it’s going for a biosimilar with a single competitor though there could be other spoilers